Arik A. Zur

机构：University of California, San Francisco, Teva Pharmaceuticals (Israel)

发表论文 13 篇 · 总被引 953 次 · h-index 11

代表论文

• OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin (2014 · Proceedings of the National Academy of Sciences · 被引 240)
• Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium (2018 · Clinical Pharmacology & Therapeutics · 被引 202)
• Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling (2012 · Journal of Medicinal Chemistry · 被引 143)
• Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1) (2018 · Journal of Medicinal Chemistry · 被引 83)
• The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin (2015 · Clinical Pharmacokinetics · 被引 58)
• LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs (2016 · Bioorganic & Medicinal Chemistry Letters · 被引 48)